BetOvac gene therapy - Oxford BioMedica

Drug Profile

BetOvac gene therapy - Oxford BioMedica

Alternative Names: BetOvac; BetOvac-MG

Latest Information Update: 13 Aug 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ovarian cancer

Most Recent Events

  • 13 Aug 2003 Discontinued - Preclinical for Ovarian cancer in United Kingdom (Injection)
  • 19 Jun 2001 BetOvac gene therapy product is in active development
  • 30 Jan 1998 Preclinical development for Ovarian cancer in United Kingdom (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top